Insider Selling: Stryker Co. (SYK) VP Sells 37,866 Shares of Stock

Share on StockTwits

Stryker Co. (NYSE:SYK) VP Katherine Ann Owen sold 37,866 shares of the stock in a transaction dated Wednesday, September 5th. The stock was sold at an average price of $166.84, for a total transaction of $6,317,563.44. Following the completion of the transaction, the vice president now owns 11,367 shares of the company’s stock, valued at $1,896,470.28. The sale was disclosed in a document filed with the SEC, which is available through this link.

NYSE:SYK traded down $1.37 on Friday, reaching $169.88. 27,297 shares of the stock traded hands, compared to its average volume of 846,585. The firm has a market cap of $62.85 billion, a P/E ratio of 26.24, a P/E/G ratio of 2.36 and a beta of 0.59. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.15 and a current ratio of 1.83. Stryker Co. has a 12 month low of $138.94 and a 12 month high of $179.84.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, July 24th. The medical technology company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.73 by $0.03. Stryker had a net margin of 8.28% and a return on equity of 26.93%. The firm had revenue of $3.32 billion during the quarter, compared to analyst estimates of $3.31 billion. During the same period in the previous year, the business posted $1.53 earnings per share. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. equities research analysts predict that Stryker Co. will post 7.25 EPS for the current year.

Several research analysts recently issued reports on SYK shares. ValuEngine upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research note on Tuesday, June 26th. Canaccord Genuity reiterated a “buy” rating and issued a $185.00 price target on shares of Stryker in a research note on Wednesday, July 25th. Royal Bank of Canada restated a “buy” rating and set a $184.00 price objective on shares of Stryker in a research note on Wednesday, July 25th. Zacks Investment Research lowered shares of Stryker from a “buy” rating to a “hold” rating in a research note on Thursday, May 24th. Finally, Cantor Fitzgerald restated a “hold” rating and set a $170.00 price objective on shares of Stryker in a research note on Wednesday, June 13th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and fifteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $177.25.

Several hedge funds have recently made changes to their positions in SYK. Fundsmith Equity Fund L.P. bought a new stake in shares of Stryker in the second quarter worth approximately $931,542,000. FMR LLC boosted its holdings in shares of Stryker by 24.0% in the second quarter. FMR LLC now owns 5,327,862 shares of the medical technology company’s stock worth $899,662,000 after buying an additional 1,032,333 shares during the last quarter. Point72 Asset Management L.P. boosted its holdings in shares of Stryker by 1,061.0% in the second quarter. Point72 Asset Management L.P. now owns 951,528 shares of the medical technology company’s stock worth $160,675,000 after buying an additional 869,568 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Stryker by 2.7% in the second quarter. BlackRock Inc. now owns 24,551,677 shares of the medical technology company’s stock worth $4,145,795,000 after buying an additional 646,505 shares during the last quarter. Finally, WCM Investment Management CA purchased a new position in shares of Stryker in the first quarter worth approximately $70,349,000. Hedge funds and other institutional investors own 75.12% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Further Reading: NASDAQ

Insider Buying and Selling by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply